New advances in the broad-spectrum influenza virus antibody vaccine

Recently, researchers from the University of Pennsylvania School of Medicine found that a broad-spectrum flu virus vaccine promises to protect people from most of the world's flu viruses.
study of the vaccine prelude, published in the latest issue of Nature Communications, has developed antibodies that target HA proteins on the surface of influenza viruses, protecting sales from infection.
although seasonal vaccines against influenza viruses are widely used, influenza viruses still cause millions of infections and hundreds of thousands of hospitalizations each year. Tens of thousands of people also die each year as a result. Unlike previous seasonal vaccines, this vaccine has a "one-time, life-long protection" effect.
instead of using HA proteins as immunogens, the vaccine uses Mrna molecules to trigger antibody reactions. When injected into the body, RNA can be identified and captured by the host's tyroblading cells, which in turn translate the molecules that produce the HA protein. This approach has a stronger immune effect than inoculation of traditional HA proteins.
authors found that there was always a strong antibody immune response in mice within 30 weeks of vaccination, and the authors also validated it in other species, such as rabbits.
addition, the immunogen corresponds to a relatively conservative area of the HA protein, so it has a potentially broad-spectrum effect.
based on these results, the authors hope to make further attempts in primates and humans.
source: Candidate for universal flu vaccines protects against multiple strains
source: Norbert Pardi et al. Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies. Nature Communications, 2018; 9 (1) DOI: 10.1038/s41467-018-05482-0 (Bio Valley)